Edition:
United Kingdom

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

58.16USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$58.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
129,040
52-wk High
$97.14
52-wk Low
$45.05

Select another date:

Thu, Dec 7 2017

BRIEF-Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

* EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT

BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98

* Eagle Pharmaceuticals Inc reports third quarter 2017 results

Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

UPDATE 1-Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Oct 27 Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

FDA tentatively approves Eagle Pharma's cancer drug

Oct 27 Eagle Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration tentatively approved its injectable drug to treat a most common type of lung cancer and a cancer of mesothelial tissue.

BRIEF-EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY

* EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY (PEMETREXED INJECTION) READY-TO-DILUTE

BRIEF-Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl

* Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited

BRIEF-EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

* EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

BRIEF-Park West Asset Management reports 5.2 percent passive stake in Eagle Pharmaceuticals as on Aug 14, 2017

* Park West Asset Management LLC reports 5.2 percent passive stake in Eagle Pharmaceuticals Inc as on August 14, 2017 - SEC filing​ Source text : (http://bit.ly/2w8Kgk2) Further company coverage:

BRIEF-Eagle Pharmaceuticals posts Q2 adj. earnings $0.49/shr

* Eagle Pharmaceuticals Inc reports second quarter 2017 results

Select another date: